145 related articles for article (PubMed ID: 15166064)
1. Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study.
Banks E; Reeves G; Beral V; Bull D; Crossley B; Simmonds M; Hilton E; Bailey S; Barrett N; Briers P; English R; Jackson A; Kutt E; Lavelle J; Rockall L; Wallis MG; Wilson M; Patnick J
BMJ; 2004 May; 328(7451):1291-2. PubMed ID: 15166064
[No Abstract] [Full Text] [Related]
2. Breast screening: the use of consensus opinion for all recalls.
Matcham NJ; Ridley NT; Taylor SJ; Cook JL; Scolding J
Breast; 2004 Jun; 13(3):184-7. PubMed ID: 15177419
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect.
Banks E; Reeves G; Beral V; Bull D; Crossley B; Simmonds M; Hilton E; Bailey S; Barrett N; Briers P; English R; Jackson A; Kutt E; Lavelle J; Rockall L; Wallis MG; Wilson M; Patnick J
Breast Cancer Res; 2006; 8(1):R8. PubMed ID: 16417651
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and mammographic screening.
Marsden J
J Br Menopause Soc; 2004 Jun; 10(2):75, 80. PubMed ID: 15207029
[No Abstract] [Full Text] [Related]
5. Influence of hormone replacement therapy on the accuracy of screening mammography.
Vernet Mdel M; Checa MA; Macià F; Casamitjana M; Carreras R
Breast J; 2006; 12(2):154-8. PubMed ID: 16509841
[TBL] [Abstract][Full Text] [Related]
6. Breast screening in women aged 40-49 years: what next?
Dickersin K
Lancet; 1999 Jun; 353(9168):1896-7. PubMed ID: 10371561
[No Abstract] [Full Text] [Related]
7. Effect of recall rate on earlier screen detection of breast cancers based on the Dutch performance indicators.
Otten JD; Karssemeijer N; Hendriks JH; Groenewoud JH; Fracheboud J; Verbeek AL; de Koning HJ; Holland R
J Natl Cancer Inst; 2005 May; 97(10):748-54. PubMed ID: 15900044
[TBL] [Abstract][Full Text] [Related]
8. [Breast cancer, mammography screening and hormone therapy].
Nielsen M
Ugeskr Laeger; 2004 Aug; 166(34):2915. PubMed ID: 15449536
[No Abstract] [Full Text] [Related]
9. [Breast cancer, mammography screening and hormone therapy].
Ersbøll J
Ugeskr Laeger; 2004 Aug; 166(36):3113-4. PubMed ID: 15387316
[No Abstract] [Full Text] [Related]
10. Cumulative false positive recall rate and association with participant related factors in a population based breast cancer screening programme.
Castells X; Molins E; Macià F
J Epidemiol Community Health; 2006 Apr; 60(4):316-21. PubMed ID: 16537348
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
Glass AG; Lacey JV; Carreon JD; Hoover RN
J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
[TBL] [Abstract][Full Text] [Related]
12. The influence of HRT on technical recall in the UK Breast Screening Programme: are pain, compression force, and compressed breast thickness contributing factors?
Nimmo LJ; Alston LA; McFadyen AK
Clin Radiol; 2007 May; 62(5):439-46. PubMed ID: 17398269
[TBL] [Abstract][Full Text] [Related]
13. Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network.
Cox B; Ballard-Barbash R; Broeders M; Dowling E; Malila N; Shumak R; Taplin S; Buist D; Miglioretti D;
Breast Cancer Res Treat; 2010 Dec; 124(3):793-800. PubMed ID: 20414718
[TBL] [Abstract][Full Text] [Related]
14. Breast density changes associated with hormone replacement therapy in postmenopausal women. Effects on the specifity and sensitivity of mamographic screening.
Howard JM
Eur J Gynaecol Oncol; 2006; 27(1):104; author reply 104. PubMed ID: 16550985
[No Abstract] [Full Text] [Related]
15. Predicting the risk of a false-positive test for women following a mammography screening programme.
Njor SH; Olsen AH; Schwartz W; Vejborg I; Lynge E
J Med Screen; 2007; 14(2):94-7. PubMed ID: 17626709
[TBL] [Abstract][Full Text] [Related]
16. Screening mammography--potential problems on the horizon.
Hall FM
N Engl J Med; 1986 Jan; 314(1):53-5. PubMed ID: 3940318
[No Abstract] [Full Text] [Related]
17. [Mammography in 40-year-old patients: towards a definitive clarification].
Di Maggio C; Giuseppetti GM; Gozzi G; Majorana M; Vella A; Amici F
Radiol Med; 1994 Jun; 87(6):731-5. PubMed ID: 8041922
[No Abstract] [Full Text] [Related]
18. Volume of screening mammography and performance in the Quebec population-based Breast Cancer Screening Program.
Théberge I; Hébert-Croteau N; Langlois A; Major D; Brisson J
CMAJ; 2005 Jan; 172(2):195-9. PubMed ID: 15655240
[TBL] [Abstract][Full Text] [Related]
19. Should women 40 to 49 years of age be offered mammographic screening?
Trop I; Deck W
Can Fam Physician; 2006 Sep; 52(9):1050-2. PubMed ID: 17279208
[No Abstract] [Full Text] [Related]
20. Screening and diagnostic mammograms: why the gold standard does not shine more brightly.
Sobti A; Sobti P; Keith LG
Int J Fertil Womens Med; 2005; 50(5 Pt 1):199-206. PubMed ID: 16468469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
